Isis Pharmaceuticals expects 2013 to be year of substantial growth, maturation

theflyonthewall.com

Expects initial commercial launch of Kynamro to be successful. The company added, ""Beyond Kynamro, we have a number of drugs in our pipeline that will complete later-stage clinical studies, which are designed to provide clear evidence that these drugs have the potential to work in patients in numerous different diseases. In addition, we plan to advance many other drugs in our pipeline, creating additional opportunities for significant long-term revenue. And finally, we expect to explore partnering opportunities that are the right fit for Isis and designed to provide the most benefit to our programs and drugs, the best balance of risk and commercial participation, while allowing us to continue to do what we do best, drug discovery and early drug development."

View Comments (0)